David Lewis

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 454 citations · Full text

Medicine, Oncology, Pharmacology +12

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 337 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Mats Jerkeman et al. · New England Journal of Medicine · 2022 · 216 citations · Full text

Medicine, Oncology, Pharmacotherapy +13